Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis

被引：0

|

作者：

Rovaris, M.

Cohen, J.

Goodman, A.

Comi, G.

Filippi, M.

机构：

来源：

JOURNAL OF NEUROLOGY | 2006年 / 253卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：144 / 144

页数：1

相关论文

共 50 条

[31] The effect of glatiramer acetate (copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS):: A multi-center, randomized, double blind, placebo-controlled study extended by open-label treatment
Comi, G
Filippi, M
NEUROLOGY, 1999, 52 (06) : A289 - A289
[32] A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial
Gold, Ralf
Giovannoni, Gavin
Selmaj, Krzysztof
Havrdova, Eva
Montalban, Xavier
Radue, Ernst-Wilhelm
Stefoski, Dusan
Robinson, Randy
Riester, Katherine
Elkins, Jacob
O'Neill, Gilmore
NEUROLOGY, 2012, 78
[33] A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial
Giovannoni, G.
Gold, R.
Selmaj, K.
Havrdova, E.
Montalban, X.
Radue, E. W.
Stefoski, D.
Robinson, R.
Riester, K.
Elkins, J.
O'Neill, G.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S508 - S509
[34] A multinational, multicenter, randomized, double-blind, placebo-controlled study extended by open-label treatment to study the effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis
Comi, G
Filippi, M
ANNALS OF NEUROLOGY, 1998, 44 (03) : 507 - 507
[35] A phase III multicenter, randomized, double-blind, parallel-group study of valdecoxib 40 mg vs. placebo in patients with multiple moderate or severe acute migraine headaches with or without aura
Thomas, HM
Kudrow, D
Ashford, E
Le, V
Brown, M
CEPHALALGIA, 2003, 23 (07) : 697 - 697
[36] A multinational, multicentre, randomised, parallel-group study to assess efficacy, safety, and tolerability of glatiramer acetate 40 mg injection three times a week in subjects with RRMS: baseline patient characteristics of the GALA study
Khan, O.
Rieckmann, P.
Boyko, A.
Selmaj, K.
Zivadinov, R.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 414 - 414
[37] MRI results from a randomised, double-blind, placebo controlled study of intramuscular interferon beta-1a, azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis
Zivadinov, R.
Horakova, D.
Dwyer, M. G.
Dolezal, A.
Krasensky, J.
Bergsland, N.
Cox, J. L.
Novakova, I.
Ticha, V.
Balachandran, S.
Svobodnik, A.
Seidl, Z.
Vaneckova, M.
Havrdova, E.
MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S200 - S200
[38] 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
O'Connor, P.
Filippi, M.
Amason, B.
LANCET NEUROLOGY, 2011, 10 (02): : 115 - 115
[39] 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
O'Connor, P.
LANCET NEUROLOGY, 2012, 11 (01): : 27 - 27
[40] 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (vol 8, pg 889, 2009)
O'Connor, P.
Filippi, M.
Arnason, B.
LANCET NEUROLOGY, 2009, 8 (11): : 981 - 981

← 1 2 3 4 5 →